News by subject: TRI

A new study published in Nature, conducted by the Accelerating Medicines Partnership (AMP), reports on the identification of new subtypes of rheumatoid arthritis (RA) by analyzing molecular patterns in biopsies from patient joints. These distinctions...

Mammogen, a leader in women's health and bellwether subsidiary of early detection parent company IVBH, has announced the successful completion of Clinical Laboratory Improvement Amendments (CLIA) validation for its pioneering plasma-based clinical...

Avation Medical, Inc., an innovative neuromodulation and digital health company with a mission to make wearable peripheral neuromodulation accessible to patients across a variety of clinical conditions, today announced the publication...

Scientists at deCODE genetics, a subsidiary of Amgen, have published a study on actionable genotypes detected in the Icelandic population and their association with lifespan. The results of this study are among the things that have motivated the...

MCRA, LLC, a leading medical device and biologics focused clinical research organization (CRO) and advisory firm integrating seven core services [U.S. and International Regulatory Affairs, Clinical Trial Operations, Reimbursement and Market Access,...

Kazia Therapeutics Limited , an oncology-focused drug development company, is pleased to announce that the Society of Neuro-Oncology 2023 Annual Meeting late breaking abstract entitled "PNOC022: a combination therapy trial using an adaptive platform...

In this free webinar, gain valuable knowledge of key considerations and processes involved in the start-up of cell and gene therapy studies, including site selection and staff training, ethics approvals, patient recruitment and sample management. The...

In this free webinar, learn ways to optimize dry eye disease clinical trial designs and execution for future treatments currently in the pipeline. Attendees will learn about dry eye disease trial composition, endpoint selection and methods and models...

Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving metabolic health, today announced key clinical and...

Enhanced External Counterpulsation (EECP®), a non-invasive treatment that increases blood flow, is a promising solution for patients with Angina with No Obstructive Coronary Arteries (ANOCA). Findings were presented at the American Heart Association...

The story of a clinical trial that is unlocking a new, personalized treatment approach with the power to save the lives of thousands of people living with an aggressive and deadly form of leukemia was screened at the American Public Health...

Aqtual, a precision medicine company using a novel cell-free DNA platform to develop products for chronic diseases and oncology, announced research today that demonstrates its novel platform can identify synovial gene expression signatures in...

Orbis International, Digital Diagnostics, and Deep Eye Care Foundation, Bangladesh, announce new findings demonstrating autonomous AI significantly improves the productivity of medical caregivers testing for diabetic eye disease by 40%. The...

IceCure Medical Ltd. , developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by...

Chemomab Therapeutics Ltd. (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory...

The PolG Foundation is a nascent foundation established in 2022 by a PolG family, with the mission to support and accelerate research to find effective treatments and a cure for PolG mitochondrial disorders.  To view the Multimedia News Release,...

RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a commercial-stage biotechnology company, is invited to present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral...

24-Week data show TPN-101 is the first treatment for PSP to reduce NfL levels, a key biomarker of neurodegeneration in tauopathies such as PSP and Alzheimer's disease TPN-101 also showed a reduction in IL-6 cytokine levels, a biomarker of...

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new...

Presented preliminary Phase 1 clinical data from ALKOVE-1 trial of NVL-655, initiated Phase 2 portion of ARROS-1 trial of NVL-520, and continued advancement of NVL-330 toward clinical development Appointed industry veteran Perrin Wilson Ph.D. as...

Seven in ten people living with diabetes (72%) only found out they had diabetes after developing complications associated with the condition. Additionally, almost all (94%) of those surveyed had experienced...

Seven in ten people living with diabetes (72%) only found out they had diabetes after developing complications associated with the condition. Additionally, almost all (94%) of those surveyed had experienced...

Brii Biosciences Limited...

Verantos, the global leader in high-validity real-world evidence at scale, today announced the presentation of an abstract on the use of artificial intelligence in cardiometabolic conditions. The technology enables researchers to gather high-quality...

...

New research, presented today at the American Heart Association's Late Breaking Science Sessions, has found that AI technology from Caristo Diagnostics can predict fatal and non-fatal cardiac events independently from routine clinical risk scores and...

Lipocine Inc. , a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of its Phase 2 study evaluating LPCN 1148 are being presented at The American Association for the...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced late-breaking clinical data from its first-in-class autologous hepatitis B...

Once-daily topical treatment of target cutaneous neurofibromas (cNFs) with NFX?179 Gel 1.5% achieved statistically significant reduction in size First randomized, double-blind, vehicle-controlled Phase 2b clinical trial to report positive results in...

Tarsier Pharma, Ltd., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing first-in-class new therapies...

NeuroSense Therapeutics Ltd. ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has concluded a successful Type D meeting with the U.S. Food and Drug Administration (FDA) for PrimeC in the...

Eko Health, Inc. (Eko), a leader in AI technology for heart and lung disease detection, today unveiled new clinical data at the 2023 American Heart Association Scientific Sessions. This data demonstrated the real-world clinical efficacy of Eko's...

Abbott announced new late-breaking data that show advanced heart failure patients living with its HeartMate 3tm...

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies...

OliPass Corporation, an RNA therapeutics platform company, disclosed uncanny clinical findings from a multi-center Phase 2a trial with Nav1.7 selective OLP-1002 in osteoarthritis (OA) patients with moderate to severe pain in Australia with Novotech....

Discover a...

?        MB-106: CR rate of 38% (N=8) with durability up to 8 months ?        Builds on CRi rate of 60% in MB-105 monotherapy AML trial last cohort (N=5) ?        MB-107: Phase 1B median extended overall survival of 11 months for heavily pre-treated...

CymaBay Therapeutics, Inc. , a biopharmaceutical company focused on innovative therapies...

In response to the growing unmet need for real-world evidence (RWE) surrounding metabolic liver diseases, industry leader Target RWE released new updates on TARGET-NASH, one of the largest real-world datasets of its kind....

AnchorDx, a leading diagnostics company developing cancer early detection tests, announced today that it has entered into a long-term collaboration with DiaCarta, a precision molecular diagnostics company and developer of novel oncology and...

Viatris Inc. , a global healthcare company, and Theravance Biopharma, Inc. today announced positive results from the YUPELRI® (revefenacin) Phase III placebo-controlled clinical trial conducted in China assessing the efficacy and safety of YUPELRI,...

PYC has developed a new drug candidate for the >5 million people worldwide[1] with Polycystic Kidney Disease (PKD)This drug candidate has demonstrated efficacy in human models derived from the kidneys of patients with end-stage renal failure due...

Mozart Therapeutics, a leading developer of CD8 Treg Modulators for the treatment of autoimmune and inflammatory diseases, presented preclinical pharmacology and tolerability data for MTX-101,a CD8 Treg modulator at the annual meeting of the American...

Chemomab Therapeutics Ltd. (Chemomab), a clinical stage biotechnology...

Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, rare disease and neuroscience, and Medison Pharma ("Medison"), a global pharma company focused on providing access to...

Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces the publication of a peer-reviewed article titled 'Knockout or inhibition of USP30 protects dopaminergic...

Medivir AB , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that clinical data from the ongoing phase 1b/2a study of in fostroxacitabine bralpamide (fostrox) in...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces late-breaking abstract poster presentation of interim results from Phase IIb expansion cohort of ASC22 (Envafolimab) for functional cure of chronic hepatitis B (CHB), and abstract poster...

Telix Pharmaceuticals Limited today announces that the first patient has been dosed in the Company's Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting radio-antibody drug conjugate (rADC)...

A recent study from Hospital for Special Surgery (HSS) and others has found a correlation between obesity and more severe disease flare symptoms that negatively affect quality of life in patients with early rheumatoid arthritis (RA), a systemic,...